Kymera Therapeutics (KYMR) Net Income Growth (3y) (2022 - 2026)

Kymera Therapeutics (KYMR) Net Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.16%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Kymera Therapeutics 10.84 Bn 10.19 Bn - -63.86%

Historic Data

Download Data
DateValue
Mar 31, 2026 -63.86%
Dec 31, 2025 -36.27%
Sep 30, 2025 -53.67%
Jun 30, 2025 -36.86%
Mar 31, 2025 -5.24%
Dec 31, 2024 -33.35%
Sep 30, 2024 6.45%
Jun 30, 2024 21.33%
Mar 31, 2024 -1.85%
Dec 31, 2023 -142.07%
Sep 30, 2023 -6.80%
Jun 30, 2023 -127.29%
Mar 31, 2023 -115.21%
Dec 31, 2022 -48.50%
Sep 30, 2022 -99.63%